spot_img
4.4 C
London
HomeHealth & FitnessChildhood Asthma: A Digital Therapy Soon Covered by French Health Insurance

Childhood Asthma: A Digital Therapy Soon Covered by French Health Insurance

For the first time in France, a digital therapy has received a favorable opinion from health authorities paving the way for reimbursement by France's national health insurance system (Assurance Maladie). The National Commission for the Evaluation of Medical Devices (CNEDiMTS), which operates under the Haute Autorité de Santé (HAS, the French National Authority for Health), validated the clinical value of “Joe” in early April 2026, a device designed for children with asthma. The decision could pave the way for an entire generation of health apps to be covered in the same way as medication.



A Small Robot to Help Manage Treatment


Developed by the French start-up Ludocare, “Joe” combines an interactive unit with a built-in screen and a companion app for parents. The goal is simple: to help children ages 7 to 11 with persistent asthma stick to their maintenance treatment, the kind that tends to get neglected once symptoms ease up. The device accompanies the child day to day, sends reminders for doses, and turns medical follow-up into a playful interaction rather than a chore.


Asthma affects roughly 14 to 16 percent of children in France, making it one of the most common chronic conditions among young people. Poor adherence to maintenance treatment remains one of the leading causes of preventable flare-ups and emergency room visits.



A Favorable Opinion, With Conditions


In its opinion dated April 2, 2026, the CNEDiMTS recognized “Joe” as having sufficient expected benefit, with a minor level of clinical improvement (ASA IV, the French rating scale for added clinical value). Clinical data show a notable reduction in flare-ups among 7- to 11-year-olds using the device alongside standard treatment. However, no superiority could be demonstrated in younger children, between ages 4 and 7, who remain excluded from the scope of this opinion.



  • An initial review in 2025 had been unfavorable, due to insufficient data.

  • New clinical data made this recognition possible in 2026.

  • Actual reimbursement still depends on a decision from the ministry in charge of health.

  • Ludocare will need to carry out a twelve-month real-world study to confirm long-term effectiveness.



Why This Decision Matters Beyond Asthma


The market for digital therapies (DTx) is booming in France, with apps already targeting sleep disorders and certain anxiety disorders, always built on an evidence-based approach rather than simple wellness claims. The opinion granted to “Joe” marks a symbolic milestone: it is the first time a purely digital intervention has crossed this threshold in France, whereas several neighboring countries have already been reimbursing this type of device for a few years.


For the families involved, the stakes are concrete: if the ministry approves coverage, access to the device will no longer depend solely on parents' financial means. For health care professionals, this official recognition also provides a clearer framework for prescribing this type of tool, which until now has been hard to distinguish from the countless wellness apps lacking clinical validation. A point worth keeping in mind to better navigate a fast-growing digital health landscape, which you can explore further in our everyday health tips.



Frequently Asked Questions


What is a digital therapy (DTx)?


It's a software-based medical device, often an app or a connected object, designed to prevent, manage, or treat a condition based on clinical evidence evaluated by health authorities, unlike a typical wellness app.


Is the “Joe” device already reimbursed?


Not yet. The CNEDiMTS issued a favorable opinion, but actual reimbursement by the Assurance Maladie depends on a final decision from the ministry in charge of health, which is still pending.


Which children are covered?


The favorable opinion applies only to children ages 7 to 11 with persistent asthma. No clinical superiority was demonstrated for children ages 4 to 7, who are therefore not covered by this evaluation.



Find more news on health and innovations in tech and digital on our dedicated pages.



Sources


Septembre Bouge: France Relaunches Physical Activity for Back-to-School

From September 1 through September 30, France is holding its very first edition of Septembre Bouge (France's new “Move in September” campaign), the national month dedicated to physical activity and sports led by the Ministries of Sports and Health. This…

Kombucha and Kefir: What These Fermented Drinks Really Do for Your Health

On supermarket shelves in France, bottles of kombucha and kefir have taken up a spot nobody would have predicted three years ago. Driven by a generation looking for alternatives to soda, these fermented drinks are posting spectacular growth — but…

Exercise and the Brain: What the 2026 Study on New Neurons Reveals

Exercise doesn't just build muscle in your legs or strengthen your heart: it also acts directly on your brain. A study published in early 2026 by researchers at the University of Cincinnati sheds new light on a phenomenon long debated…

Sleep Loss and Weight Gain: The Real Culprit Isn't Hunger

Sleep loss has long been presented as a simple matter of fatigue. A recent American study, however, challenges a deeply rooted assumption: it's not hunger that drives weight gain when we sleep less, but rather the drop in energy that…

This article was written with the help of artificial intelligence. Editorial policy

Les derniers articles

En découvrir plus

Editorial policy and use of artificial intelligence